RALEIGH, N.C., Feb. 4 /PRNewswire/ -- CLOSURE Medical Corporation
(Nasdaq: CLSR) today announced that it has been registered by British
Standards Institution (BSI) as being in compliance with ISO-9001 standards,
the most extensive of the quality assurance, standards for manufacturing and
service firms as issued by the International Organization of Standardization
of Geneva, Switzerland.
    "We are extremely pleased that a company-wide commitment to excellence in
our quality assurance systems has gained CLOSURE this designation," said Mr.
Robert V. Toni, President and Chief Executive Officer.  "The medical device
companies that achieve and retain this registration must consistently meet
customer expectations and demonstrate through repeated, independent audits
that they have a functioning, documented method for continuous quality
improvement."
    In March 1996, the Company entered into a marketing agreement with
Ethicon, Inc., a subsidiary of Johnson & Johnson, for exclusive worldwide
marketing and distribution of DERMABOND*, its tissue cohesive for topical
applications.
    The ISO-9001 registration along with the previously awarded CE Mark, for
DERMABOND enhances CLOSURE's ability to support Ethicon's marketing and
distribution of DERMABOND, skin tissue cohesive for topical applications, in
the European market.
    CLOSURE Medical develops, commercializes and manufactures medical cohesive
products based on its proprietary cyanoacrylate technology.  CLOSURE's
"nonabsorbable" products may be used to replace sutures and staples for
certain topical wound closure applications, while its "absorbable" products
can potentially be used as surgical sealants and adhesives for internal wound
closure and management.  Currently marketed products include Octyldent(R),
used in conjunction with antibiotics to treat adult periodontal disease,
Nexaband(R), a line of topical cohesives used in veterinary wound closure and
management, and DERMABOND, a non-absorbable cohesive used for certain topical
wound closure applications.

    * DERMABOND is a trademark of Ethicon, Inc., a subsidiary of Johnson &
Johnson.

    To receive CLOSURE's latest news release and other corporate documents via
FAX -- at no cost -- dial 1-800-PRO-INFO.  Use Company's ticker-CLSR.

    This release contains certain forward-looking statements which involve
known and unknown risks, delays, uncertainties or other factors not under the
Company's control which may cause actual results, performance or achievements
of the Company to be materially different from the results, performance, or
other expectations implied by these forward-looking statements.  These factors
include, but are not limited to, the early stage of commercialization of the
Company's products; scale-up of manufacturing processes; the need for
regulatory approval and effects of governmental regulation; technological
uncertainties; dependence on marketing partners; and dependence on patents and
trade secrets, as well as those detailed in the Company's Annual Report on
Form 10-K for the year ended December 31, 1996 and filed with the Securities
and Exchange Commission.

Link to this page: